Stay updated with breaking news from T Cells. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In this final of 3 segments of an interview with ICT, Thomas Rademacher, Emergex co-founder, delves into T cell-based vaccines for chikungunya, likening immune programming to software, emphasizing the urgency of prevention in endemic regions.
Avoiding relapse could also help increase rates of survival, researchers say.
Consider the comparison of generation, phenotype, and efficacy of CAR-T cells produced using TcBuster, and other systems
“I thought every time you catch an illness it’s supposed to be a bit better each time?” was the message from his sickbed.
Stanford University researchers investigate how novel cancer treatment CAR T therapy can reactivate a strain of herpes virus in a minority of patients.